Given the unprecedented speed at which this work was done, our AI helped provide the researchers with peace of mind that no study was left behind.
HAMILTON, Ontario (PRWEB) June 05, 2020
Evidence Prime Inc. announced today that its system for conducting Living Systematic Reviews (laser.ai) was successfully applied to verify screening decisions in the study published on June 1st in The Lancet https://doi.org/10.1016/S0140-6736(20)31142-9 by international COVID-19 Systematic Urgent Review Group Effort (SURGE) group. The paper provides the best available evidence based on 172 studies. It answers pressing questions, such as the optimal physical distance and universal use of face masks, and was commissioned by the World Health Organization.
“We see a lot of mixed guidance from public health authorities around the world on what preventive measures should be applied to reduce the spread of COVID-19. This study provides the long-awaited summary of the best available evidence on this topic“, says Artur Nowak, CTO at Evidence Prime. “Given the unprecedented speed at which this work was done, our AI helped provide the researchers with peace of mind that no study was left behind”.
Laser.ai allows the semi-automated synthesis of evidence, expediting the process and enabling living (always up-to-date) systematic reviews. The work is supported by the European Union under the European Regional Development Fund via the "LaSeR" project (a “Fast Track to Innovation” program by the Polish National Centre for Research and Development).
About Evidence Prime: Evidence Prime is a provider of highly specialized, AI-driven software solutions for evidence-based healthcare. It develops GRADEpro, used by more than 65,000 users worldwide for creating evidence synthesis, clinical practice guidelines, and decision aids. For more information, visit https://evidenceprime.com.